secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001493152-25-019706
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma receives ~$500K NIH SBIR award for influenza antiviral program
-------------------------------------------------------------------------------

- Award from NIH/NIAID to support development of novel oral broad-spectrum antiviral for influenza A and B.
- Approximately $500,000 in non-dilutive funding; Phase I award to assess scientific and commercial potential.
- Funds will be used to characterize lead candidate molecules inhibiting the influenza polymerase complex.
- Successful Phase I completion may qualify Cocrystal to apply for a larger Phase II award.
- Company continues to pursue additional non-dilutive government and military funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315225019706/0001493152-25-019706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315225019706/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-019706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer